Evaluation of Gentamicin Ototoxicity in Newborn Infants: A Retrospective Observational Study

Basit Öğe Kaydı
dc.contributor.authorEkmen, Sadrettin
dc.contributor.authorDogan, Erkan
dc.date.accessioned2024-09-29T16:06:42Z
dc.date.available2024-09-29T16:06:42Z
dc.date.issued2021
dc.departmentKarabük Üniversitesien_US
dc.description.abstractBackground The main purpose of this study was to demonstrate the effect of gentamicin on hearing tests in newborns treated with gentamicin in our NICU, and to contribute to the selection of antibiotics more consciously. Materials and Methods: Infants who Nvere hospitalized and followed up in the NICU of Karabuk University Medical Faculty Hospital, Karabuk, Turkey, between December 2019 and November 2020 were included in our study. During the study period, 331 infants hospitalized in the NICU and meeting the inclusion criteria were included.The infants were divided into two groups, with and without gentamicin treatment, and their demographic characteristics, respiratory support treatment and hearing test results were retrospectively analyzed and the results were compared. Automated auditory brainstem response (ABR) was used for newborn hearing screening at discharge. Results: Demographically, maternal age and birth weight were found to be significantly lower in gentamicin patients. Delivery method and gestational age were similar between the two groups. While the rates of passing the first test in the ABR screening were higher in the gentamicin group (p=0.051), only 1 infant in the same group failed the ABR second screening. This infant was 34 weeks old, a fraternal twin born at 2200 g, and no hearing loss was found in the infant's twin. When the anamnesis was observed in detail, the infants' uncle manifested a history of hospitalization for the treatment of urinary tract infection in his youth. In the meantime, his history of amikacin treatment and consequent experience of sensorineural hearing loss was revealed. Conclusion We concluded that gentamicin does not affect the hearing test when it is not used in the short-term (5-7 days), extended dosing intervals (24-48 hours), and ototoxic drugs such as loop diuretics.en_US
dc.identifier.doi10.22038/IJP.2021.55656.4383
dc.identifier.endpage13144en_US
dc.identifier.issn2345-5047
dc.identifier.issn2345-5055
dc.identifier.issue3en_US
dc.identifier.startpage13137en_US
dc.identifier.urihttps://doi.org/10.22038/IJP.2021.55656.4383
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7000
dc.identifier.volume9en_US
dc.identifier.wosWOS:000632990500004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMashhad Univ Med Sciencesen_US
dc.relation.ispartofInternational Journal of Pediatrics-Mashhaden_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInfantsen_US
dc.subjectGentamicinen_US
dc.subjectOtotoxicityen_US
dc.subjecthearingen_US
dc.subjectNICUen_US
dc.titleEvaluation of Gentamicin Ototoxicity in Newborn Infants: A Retrospective Observational Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu